Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. Receivables for the year ending December 31, 2023: USD 65.42 M

Pulike Biological Engineering, Inc. Receivables is USD 65.42 M for the year ending December 31, 2023, a -10.91% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Pulike Biological Engineering, Inc. Receivables for the year ending December 31, 2022 was USD 73.43 M, a 50.66% change year over year.
Pulike Biological Engineering, Inc. Receivables for the year ending December 31, 2021 was USD 48.74 M, a 50.32% change year over year.
Pulike Biological Engineering, Inc. Receivables for the year ending December 31, 2020 was USD 32.43 M, a 66.75% change year over year.
Pulike Biological Engineering, Inc. Receivables for the year ending December 31, 2019 was USD 19.45 M, a -8.78% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Healthcare
Industries Biotechnology Pet Food Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years